Free Trial
NASDAQ:SPRO

Spero Therapeutics (SPRO) Stock Price, News & Analysis

Spero Therapeutics logo
$1.98 +0.13 (+7.03%)
Closing price 08/27/2025 04:00 PM Eastern
Extended Trading
$1.97 -0.01 (-0.51%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Spero Therapeutics Stock (NASDAQ:SPRO)

Key Stats

Today's Range
$1.85
$2.01
50-Day Range
$1.83
$3.04
52-Week Range
$0.51
$3.22
Volume
554,715 shs
Average Volume
757,155 shs
Market Capitalization
$111.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
Consensus Rating
Moderate Buy

Company Overview

Spero Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
82nd Percentile Overall Score

SPRO MarketRank™: 

Spero Therapeutics scored higher than 82% of companies evaluated by MarketBeat, and ranked 200th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Spero Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Spero Therapeutics has received no research coverage in the past 90 days.

  • Read more about Spero Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Spero Therapeutics are expected to grow in the coming year, from ($1.20) to ($0.79) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Spero Therapeutics is -2.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Spero Therapeutics is -2.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Spero Therapeutics has a P/B Ratio of 3.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Spero Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    2.61% of the float of Spero Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Spero Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Spero Therapeutics has recently increased by 13.11%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Spero Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Spero Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.61% of the float of Spero Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Spero Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Spero Therapeutics has recently increased by 13.11%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Spero Therapeutics has a news sentiment score of 1.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Spero Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    Only 1 people have searched for SPRO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Spero Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Spero Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.50% of the stock of Spero Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 25.60% of the stock of Spero Therapeutics is held by institutions.

  • Read more about Spero Therapeutics' insider trading history.
Receive SPRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SPRO Stock News Headlines

NVIDIA's Worst Nightmare?
$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the REAL fortune they expect to come from quantum computing - a $2 trillion explosion by 2035. The kicker? One company is America's FIRST commercial supplier of the material that makes it possible.tc pixel
See More Headlines

SPRO Stock Analysis - Frequently Asked Questions

Spero Therapeutics' stock was trading at $1.03 at the beginning of 2025. Since then, SPRO shares have increased by 92.2% and is now trading at $1.98.

Spero Therapeutics, Inc. (NASDAQ:SPRO) released its quarterly earnings results on Tuesday, August, 12th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.38) by $0.35. The firm earned $14.19 million during the quarter, compared to analysts' expectations of $11 million. Spero Therapeutics had a negative net margin of 110.35% and a negative trailing twelve-month return on equity of 120.27%.
Read the conference call transcript
.

Spero Therapeutics (SPRO) raised $75 million in an IPO on Thursday, November 2nd 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

Top institutional investors of Spero Therapeutics include Geode Capital Management LLC (0.91%), Stonepine Capital Management LLC (0.28%), Group One Trading LLC and Bridgeway Capital Management LLC (0.20%). Insiders that own company stock include Aquilo Capital Management, Llc, Sath Shukla, Esther Rajavelu, Ankit Mahadevia, Kamal Hamed and Timothy Keutzer.
View institutional ownership trends
.

Shares of SPRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Spero Therapeutics investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), Meta Platforms (META), NVIDIA (NVDA), Editas Medicine (EDIT) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
8/12/2025
Today
8/27/2025
Next Earnings (Estimated)
11/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SPRO
CIK
1701108
Fax
N/A
Employees
150
Year Founded
2013

Price Target and Rating

High Price Target
$5.00
Low Price Target
$5.00
Potential Upside/Downside
+152.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.98)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$68.57 million
Net Margins
-110.35%
Pretax Margin
-110.35%
Return on Equity
-120.27%
Return on Assets
-55.61%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.97
Quick Ratio
3.97

Sales & Book Value

Annual Sales
$47.98 million
Price / Sales
2.32
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.58 per share
Price / Book
3.41

Miscellaneous

Outstanding Shares
56,280,000
Free Float
53,180,000
Market Cap
$111.43 million
Optionable
Optionable
Beta
1.39

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:SPRO) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners